CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Pharmacogenomics and Personalized Medicine

Volumn 5, Issue 1, 2012, Pages 149-153

  Sirachainan, Ekaphop ^a   Jaruhathai, Sureerat ^a   Trachu, Narumol ^b   Panvichian, Ravat ^a   Sirisinha, Thitiya ^a   Ativitavas, Touch ^a   Ratanatharathorn, Vorachai ^a   Chamnanphon, Montri ^a   Sukasem, Chonlaphat ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Breast cancer; CYP2D6 polymorphism; Pharmacogenetics; Single nucleotide polymorphism (SNP); Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CYP2D6 GENE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MUTATOR GENE; OUTCOME ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND;

EID: 84868143866     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576-586.
2. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062-1075.
3. Lim YC, Li L, Desta Z, etal. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318(2):503-512.
4. Fabian C, Tilzer L, Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptor isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharma Drug Dispos. 1981;2(4):381-390.
5. Jin Y, Desta Z, Stearns V, etal. CYP2D6genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
7. Higgins MJ, Stearns V. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer. Clin Chem. 2009;55(8):1453-1455.
8. Goetz MP, Rae JM, Suman VJ, etal. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
9. Knox SK, Ingle JN, Suman VJ, etal. Cytochrome P450 2D6status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). J Clin Oncol. 2006;24(18S);504.
10. Stearns V, Johnson MD, Rae JM, etal. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758-1564.
11. Lim H-S, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007;25(25):3837-3845.
12. Borges S, Desta Z, Li L, etal. Quantitative effect of CYP2D6genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80(1):61-74.
13. Lim JSL, Chen XA, Singh O, etal. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71(5): 737-750.
14. Nowell S, Ahn J, Rae J, etal. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005; 91(3):249-258.
15. Goetz MP, Schaid DJ, Wickerham DL, etal. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res. 2011;17(21):6944-6951.
16. Schroth W, Antoniadou L, Fritz P, etal. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.
17. Schroth W, Goetz MP, Hamann U, etal. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-1436.
18. Schroth W, Hamann U, Fasching PA, etal. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res. 2010;16(17):4468-4477.
19. Kiyotani K, Mushiroda T, Sasa M, etal. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008;99(5):995-999.
20. Xu Y, Sun Y, Yao L, etal. Association between CYP2D6*10genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19(8):1423-1429.
21. Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D6*10genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol. 2009;39(10):651-656.
22. Pechatanan K, Jaruhathai S, Ativitavas T, etal. Cytochrome P450 2D6 polymorphisms of Thai breast cancer patients and their outcomes of adjuvant tamoxifen. J Clin Oncol. 2007;Suppl:Abstr e11037.
23. Bonanni B, Macis D, Maisonneuve P, etal. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flash: data from the Italian Tamoxifen Trial. J Clin Oncol. 2006;24(22):3708-3709.
24. The LK, Mohamed NI, Salleh MZ, etal. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J. 2012;14(1):52-59.
25. Fleeman N, Martin Saborido C, Payne K, etal. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess. 2011;15(33):1-102.
26. Ramamoorthy Y, Tyndale RF, Sellers EM. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001;11(6):477-487.